Zealand Pharma A/S (OTCMKTS:ZLDPF) Reaches New 52-Week Low – Here’s Why

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) hit a new 52-week low during mid-day trading on Saturday. The stock traded as low as $35.6450 and last traded at $35.6450, with a volume of 337 shares trading hands. The stock had previously closed at $37.54.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ZLDPF shares. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Barclays lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Zealand Pharma A/S presently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The firm’s 50-day moving average price is $45.83 and its 200 day moving average price is $46.24. The company has a current ratio of 13.98, a quick ratio of 13.98 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of 5.91 and a beta of 0.95.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.